

Active Pharmaceutical Ingredients

2017



PIONEER THEN,
A LEADER NOW.



HETERO

List of Drug Master Files

S.No	API Name	Status
1.	Acyclovir	USDMF/EDMF
2.	Adefovir Dipivoxil	USDMF/EDMF
3.	Alfuzosin Hydrochloride	USDMF/EDMF
4.	Amlodipine Besylate	USDMF/EDMF
5.	Apixaban	USDMF/EDMF
6.	Aripiprazole	USDMF/EDMF
7.	Atomoxetine Hydrochloride	USDMF/EDMF
8.	Atorvastatin Calcium Amorphous & Crystalline	USDMF/EDMF
9.	Atovaquone	USDMF/EDMF
10.	Bosentan Hydrate	USDMF
11.	Bupropion Hydrochloride	USDMF/EDMF
12.	Candesartan Cilexetil	USDMF/EDMF
13.	Celecoxib Form III	USDMF/EDMF
14.	Cilazapril	EDMF
15.	Cinacalcet Hydrochloride	USDMF/EDMF
16.	Citalopram Hydrobromide	USDMF/EDMF
17.	Clopidogrel Bisulphate Form I & Form II	USDMF/EDMF
18.	Cyclobenzaprine Hydrochloride	USDMF/EDMF
19.	Dabigatran Etexilate Mesylate	USDMF/EDMF
20.	Dapagliflozin	USDMF/EDMF
21.	Darifenacin Hydrobromide	USDMF/EDMF
22.	Desloratadine	USDMF/EDMF
23.	Donepezil Hydrochloride Form I & Form III	USDMF/EDMF
24.	Divalproex Sodium	USDMF/EDMF
25.	Dorzolamide Hydrochloride	USDMF/EDMF
26.	Doxazosin Mesylate	EDMF
27.	Droxidopa	USDMF/EDMF
28.	Duloxetine Hydrochloride	USDMF/EDMF
29.	Dutasteride	USDMF/EDMF
30.	Eletriptan Hydrobromide a Form	USDMF/EDMF
31.	Eltrombopag Olamine	USDMF/EDMF
32.	Empagliflozin	USDMF/EDMF
33.	Entacapone Form A	USDMF/EDMF
34.	Eprosartan Mesylate	USDMF/EDMF
35.	Escitalopram Oxalate	USDMF/EDMF
36.	Eslicarbazepine	USDMF/EDMF
37.	Esomeprazole Mg Dihydrate/ Trihydrate	USDMF/EDMF
38.	Esomeprazole Sodium	USDMF/EDMF
39.	Etoricoxib Form I	USDMF/EDMF
40.	Ezetimibe	USDMF/EDMF
41.	Famciclovir	USDMF/EDMF
42.	Febuxostat	USDMF/EDMF
43.	Fenofibrate	USDMF

The products covered under valid and enforceable patent in India, are not offered or supplied for the commercial use, until the expiration of corresponding patent. Such products will be supplied solely for the Research and Development purposes reasonably related to the development and submission of information required by Regulatory Agencies in India, or elsewhere, that regulate the manufacture, use, sale or import, of the said product i.e. according to the Section 107A of the Indian Patents Act, 1970. The buyers are requested to make their independent evaluation of the patent scenario for their respective markets and buyers will be responsible for all patent related liabilities.

S.No	API Name	Status
44.	Fesoterodine Fumarate	USDMF
45.	Fexofenadine Hydrochloride Form I	USDMF/EDMF
46.	Finasteride Form I	USDMF/EDMF
47.	Fingolimod Hydrochloride	USDMF/EDMF
48.	Fosinopril Sodium	USDMF/EDMF
49.	Gabapentin	USDMF/EDMF
50.	Ganciclovir	USDMF/EDMF
51.	Glimepiride	USDMF/EDMF
52.	Hydralazine Hydrochloride	USDMF/EDMF
53.	Irbesartan Form A	USDMF/EDMF
54.	Lacosamide Form I	USDMF/EDMF
55.	Lansoprazole	USDMF/EDMF
56.	Lercanidipine Hydrochloride	EDMF
57.	Levetiracetam	USDMF/EDMF
58.	Levofloxacin	USDMF/EDMF
59.	Levomilnacipran Hydrochloride	USDMF/EDMF
60.	Lisinopril	USDMF/EDMF
61.	Loratadine	EDMF
62.	Losartan Potassium Form I	USDMF/EDMF
63.	Lurasidone Hydrochloride	USDMF/EDMF
64.	Macitentan	USDMF/EDMF
65.	Milnacipran Hydrochloride	USDMF/EDMF
66.	Montelukast Sodium	USDMF/EDMF
67.	Moxifloxacin Hydrochloride Monohydrate/Anhydrous	USDMF/EDMF
68.	Memantine Hydrochloride Form I	USDMF/EDMF
69.	Metaxalone	USDMF
70.	Nabumetone	USDMF/EDMF
71.	Nebivolol Hydrochloride	USDMF/EDMF
72.	Olanzapine Form I	USDMF/EDMF
73.	Olmesartan Medoxomil	USDMF/EDMF
74.	Omeprazole Form A & Form B	USDMF/EDMF
75.	Omeprazole Magnesium	USDMF/EDMF
76.	Oseltamivir Phosphate Form A	USDMF/EDMF
77.	Pantoprazole Sodium	USDMF/EDMF
78.	Perindopril Erbumine	USDMF/EDMF
79.	Pioglitazone Hydrochloride	USDMF/EDMF
80.	Pitavastatin Calcium Form H1	USDMF/EDMF
81.	Pramipexole diHydrochloride	USDMF/EDMF
82.	Prasugrel Hydrochloride Form B	USDMF/EDMF
83.	Pregabalin	USDMF/EDMF
84.	Proguanil Hydrochloride	USDMF/EDMF
85.	Quetiapine Fumarate	USDMF/EDMF
86.	Rabeprazole Sodium	USDMF/EDMF

The products covered under valid and enforceable patent in India, are not offered or supplied for the commercial use, until the expiration of corresponding patent. Such products will be supplied solely for the Research and Development purposes reasonably related to the development and submission of information required by Regulatory Agencies in India, or elsewhere, that regulate the manufacture, use, sale or import, of the said product i.e. according to the Section 107A of the Indian Patents Act, 1970. The buyers are requested to make their independent evaluation of the patent scenario for their respective markets and buyers will be responsible for all patent related liabilities.

List of Drug Master Files

S.No	API Name	Status
87.	Ramipril	USDMF/EDMF
88.	Raloxifene Hydrochloride	USDMF/EDMF
89.	Riluzole	USDMF/EDMF
90.	Risedronate sodium	USDMF/EDMF
91.	Rizatriptan Benzoate	USDMF/EDMF
92.	Rosuvastatin Calcium	USDMF/EDMF
93.	Roflumilast	USDMF/EDMF
94.	Rufinamide	USDMF/EDMF
95.	Saxagliptin	USDMF/EDMF
96.	Sertraline Hydrochloride Form I & Form II	USDMF/EDMF
97.	Sevelamer Hydrochloride & Carbonate	USDMF/EDMF
98.	Sildenafil Citrate	USDMF/EDMF
99.	Simvastatin	USDMF/EDMF
100.	Solifenacin Succinate	USDMF/EDMF
101.	Silodosin a Form/b Form	USDMF/EDMF
102.	Telmisartan	USDMF/EDMF
103.	Terbinafine Hydrochloride	USDMF/EDMF
104.	Tetrabenazine	USDMF/EDMF
105.	Tolvaptan	USDMF/EDMF
106.	Tolterodine Tartrate Form I	USDMF/EDMF
107.	Topiramate	USDMF/EDMF
108.	Torsemide	USDMF/EDMF
109.	Valacyclovir Hydrochloride	USDMF/EDMF
110.	Valganciclovir	USDMF/EDMF
111.	Valsartan	USDMF/EDMF
112.	Voriconazole Form I	USDMF/EDMF
113.	Vortioxetine HBr	USDMF/EDMF
114.	Zolmitriptan	USDMF/EDMF
115.	Zonisamide	USDMF/EDMF
116.	Ziprasidone Hydrochloride	USDMF/EDMF

ANTIRETROVIRALS

1.	Abacavir Sulphate	USDMF/EDMF
2.	Atazanavir Sulphate	USDMF/EDMF
3.	Darunavir Amorphous & Ethanolate	USDMF/EDMF
4.	Didanosine	USDMF/EDMF
5.	Efavirenz Form I	USDMF/EDMF
6.	Emtricitabine	USDMF/EDMF
7.	Entecavir	USDMF/EDMF
8.	Etravirine Form I	USDMF/EDMF
9.	Lamivudine Form I & Form II	USDMF/EDMF
10.	Lopinavir Form I & Amorphous	USDMF/EDMF
11.	Maraviroc Form B & Amorphous	USDMF/EDMF

The products covered under valid and enforceable patent in India, are not offered or supplied for the commercial use, until the expiration of corresponding patent. Such products will be supplied solely for the Research and Development purposes reasonably related to the development and submission of information required by Regulatory Agencies in India, or elsewhere, that regulate the manufacture, use, sale or import, of the said product i.e. according to the Section 107A of the Indian Patents Act, 1970. The buyers are requested to make their independent evaluation of the patent scenario for their respective markets and buyers will be responsible for all patent related liabilities.

S.No	API Name	Status
12.	Nevirapine Form I	USDMF/EDMF
13.	Raltegravir Potassium Form I & Amorphous	USDMF/EDMF
14.	Ritonavir Form I & Amorphous Premix	USDMF/EDMF
15.	Saquinavir Mesylate	USDMF/EDMF
16.	Stavudine	USDMF/EDMF
17.	Tenofovir Disoproxil Fumarate	USDMF/EDMF
18.	Zidovudine	USDMF/EDMF
19.	Fosamprenavir Calcium	Technical Package

ANTINEOPLASTICS

1.	Abiraterone Acetate	USDMF/EDMF
2.	Anastrozole	USDMF/EDMF
3.	Aprepitant	USDMF/EDMF
4.	Azacitidine	USDMF/EDMF
5.	Bendamustine Hydrochloride	USDMF/EDMF
6.	Bexarotene	USDMF/EDMF
7.	Bicalutamide	USDMF/EDMF
8.	Bortezomib	USDMF/EDMF
9.	Cabazitaxel Form C	USDMF
10.	Capecitabine	USDMF/EDMF
11.	Carboplatin	USDMF/EDMF
12.	Cisplatin	USDMF/EDMF
13.	Cyclophosphamide	USDMF/EDMF
14.	Docetaxel	USDMF/EDMF
15.	Erlotinib Hydrochloride Form A	USDMF/EDMF
16.	Fosaprepitant Dimeglumine	USDMF/EDMF
17.	Gefitinib	USDMF/EDMF
18.	Gemcitabine Hydrochloride	USDMF/EDMF
19.	Imatinib Mesylate Amorphous/ a Form/ b Form	USDMF/EDMF
20.	Irinotecan Hydrochloride	USDMF/EDMF
21.	Lapatinib Ditosylate	USDMF/EDMF
22.	Lenalidomide Form H/Form B	USDMF/EDMF
23.	Letrozole	USDMF/EDMF
24.	Nilotinib Hydrochloride Dihydrate Form A	USDMF/EDMF
25.	Oxaliplatin	USDMF/EDMF
26.	Paclitaxel	USDMF/EDMF
27.	Pazopanib Hydrochloride	USDMF/EDMF
28.	Pemetrexed Disodium 2.5 Hydrate/7.0 Hydrate	USDMF/EDMF
29.	Plerixafor	USDMF/EDMF
30.	Pralatrexate Form A	USDMF/EDMF
31.	Sorafenib Tosylate Form III	USDMF/EDMF
32.	Sunitinib Malate Form I/Base	USDMF/EDMF
33.	Temozolomide Form III	USDMF/EDMF

The products covered under valid and enforceable patent in India, are not offered or supplied for the commercial use, until the expiration of corresponding patent. Such products will be supplied solely for the Research and Development purposes reasonably related to the development and submission of information required by Regulatory Agencies in India, or elsewhere, that regulate the manufacture, use, sale or import, of the said product i.e. according to the Section 107A of the Indian Patents Act, 1970. The buyers are requested to make their independent evaluation of the patent scenario for their respective markets and buyers will be responsible for all patent related liabilities.

List of New Products

S.No	API Name	Status
34.	Thalidomide	USDMF/EDMF
35.	Zoledronic Acid Form I	USDMF/EDMF

ANTINEOPLASTICS - New Products

36.	Afatinib Dimaleate	USDMF
37.	Axitinib Form IV	USDMF
38.	Crizotinib/ Premix	USDMF/EDMF
39.	Enzalutamide	USDMF
40.	Ibrutinib	USDMF/EDMF
41.	Melphalan Hydrochloride	USDMF/EDMF
42.	Regorafenib Form I	USDMF/EDMF
43.	Pomalidomide Form A	USDMF
44.	Tamoxifen Citrate	USDMF
45.	Trametinib Dimethylsulfoxide	USDMF
46.	Bosutinib	Technical Package
47.	Cabozantinib	Technical Package
48.	Carfilzomib	Technical Package
49.	Ceritinib	Technical Package
50.	Idelalisib	Technical Package
51.	Nintedanib	Technical Package
52.	Olaparib	Technical Package
53.	Palbociclib	Technical Package
54.	Vemurafenib	Technical Package
55.	Vismodegib	Technical Package

HEPATITIS-C, CHRONIC - ANTIVIRALS

1.	Daclatasvir Di Hydrochloride	USDMF
2.	Ledipasvir	USDMF
3.	Sofosbuvir	USDMF
4.	Velpatasvir	Technical Package

List of New Products

1.	Alogliptin Benzoate Form A	USDMF/EDMF
2.	Avanafil	USDMF
3.	Azilsartan Kamedoxomil Form I	USDMF/EDMF
4.	Canagliflozin	USDMF
5.	Cilnidipine	USDMF
6.	Clobazam	USDMF
7.	Cobicistat	USDMF/EDMF
8.	Dimethyl Fumarate	USDMF
9.	Elvitegravir Form III	USDMF
10.	Linagliptin/Premix	USDMF

The products covered under valid and enforceable patent in India, are not offered or supplied for the commercial use, until the expiration of corresponding patent. Such products will be supplied solely for the Research and Development purposes reasonably related to the development and submission of information required by Regulatory Agencies in India, or elsewhere, that regulate the manufacture, use, sale or import, of the said product i.e. according to the Section 107A of the Indian Patents Act, 1970. The buyers are requested to make their independent evaluation of the patent scenario for their respective markets and buyers will be responsible for all patent related liabilities.

S.No	API Name	Status
11.	Mirabegron a Form/b Form	USDMF
12.	Ospemifene	USDMF
13.	Pirfenidone	USDMF
14.	Posaconazole Form I	USDMF/EDMF
15.	Rilpivirine Hydrochloride	USDMF/EDMF
16.	Sitagliptin Phosphate/Hydrochloride	USDMF/EDMF
17.	Tadalafil Form I	USDMF
18.	Tenofovir Alafinamide	USDMF
19.	Teriflunomide	USDMF
20.	Ticagrelor Form II	USDMF/EDMF
21.	Vildagliptin	EDMF
22.	Acotiamide Hydrochloride Trihydrate	Technical Package
23.	Apremilast	Technical Package
24.	Azithromycin Dihydrate	Technical Package
25.	Bedaquiline Fumarate	Technical Package
26.	Brexpiprazole	Technical Package
27.	Brivaracetam	Technical Package
28.	Colesevelam Hydrochloride	Technical Package
29.	Congrelor Tetrasodium	Technical Package
30.	Dalfampridine/ Fampridine	Technical Package
31.	Dexlansoprazole	Technical Package
32.	Edoxaban Tosilate	Technical Package
33.	Gemigliptin	Technical Package
34.	Ivabradine Hydrochloride Premix	Technical Package
35.	Ivacaftor	Technical Package
36.	Lesinurad	Technical Package
37.	Lomitapide Mesylate	Technical Package
38.	Obeticholic Acid	Technical Package
39.	Omarigliptin	Technical Package
40.	Oxcarbazepine	Technical Package
41.	Ponatinib Hydrochloride	Technical Package
42.	Rupatadine Fumarate	Technical Package
43.	Sacubitril + Valsartan.	Technical Package
44.	Selexipag	Technical Package
45.	Suvorexant	Technical Package
46.	Teneligliptin Hydrobromide	Technical Package
47.	Tofacitinib Citrate	Technical Package
48.	Trelagliptin Succinate	Technical Package
49.	Vorapaxar	Technical Package

The products covered under valid and enforceable patent in India, are not offered or supplied for the commercial use, until the expiration of corresponding patent. Such products will be supplied solely for the Research and Development purposes reasonably related to the development and submission of information required by Regulatory Agencies in India, or elsewhere, that regulate the manufacture, use, sale or import, of the said product i.e. according to the Section 107A of the Indian Patents Act, 1970. The buyers are requested to make their independent evaluation of the patent scenario for their respective markets and buyers will be responsible for all patent related liabilities.

Why partner Hetero?

- 20+ years of expertise in pharmaceuticals
- Vertically integrated pharmaceutical company
- World-class R&D supported by cutting-edge technologies
- Global leader in ARV APIs and Finished Dosages
- 25+ manufacturing facilities approved by global regulatory authorities
- Compliance to cGMP practices ensuring high-quality standards
- Portfolio of 200+ products
- Established presence in 120+ countries
- Trusted Partner of Choice for customers around the world

Asia's largest API manufacturing complex, Visakhapatnam, India



For more information on Hetero, please visit
www.heteroworld.com



HETERO

Hetero Corporate,
7-2-A2, Industrial Estates,
Sanath Nagar, Hyderabad – 500 018, Telangana, INDIA
Phone: +91 40 23704923/24/25 Fax: +91 40 23813359, 23704926
Email: businessenquiries@heterodrugs.com